Abstract
delivery of IL-22BP gene was performed into the proximal colon of DSS-treated WT mice. As predicted, significantly enhanced IL-22BP expression was observed in the injected site. The IL-22BP-gene delivery significantly inhibited the activation of STAT3 in CECs within the injected, but not non-injected, sites of the colon. Most importantly, the IL-22BP gene delivery exacerbated the inflammation as judged by presence of severe ulcerations.CONCLUSION: We herein develop a novel microinjection-based local gene delivery system that is capable of targeting inflamed mucosa and may provide a means to develop a new therapeutic strategy for treating mucosal inflammation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
